title: [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
abstract: OBJECTIVE
  To compare the efficacy of nateglinide with repaglinide in the treatment of type 2 diabetes mellitus.
  
  
  METHODS
  Forty-six type 2 diabetic patients were randomly treated with repaglinide (group A, 1.0 mg tid, n=23) or nateglinide (group B, 90.0 mg tid, n=23). The trial consisted of a 4-week equilibrated period followed by 12 weeks of treatment course.
  
  
  RESULTS
  In group A, the fasting blood glucose (FBG) and 30-, 60-, 120- min postprandial blood glucose (PBG), as well as hemoglobin A1c were decreased significantly (P<0.05). In group B, the 60-min and 120-min PBG decreased remarkably (P<0.05), but FBG, 30-min PBG and A1c decreased with no statistical significance (P>0.05). After 12 weeks treatment, the 30-, 60-, 120-min postprandial insulin level, area under the curve of insulin and C peptide (0 to 120 min) increased in both groups (P<0.05). No significant difference was found between the effects of repaglinide and nateglinide on early phase insulin secretion.
  
  
  CONCLUSIONS
  The glucose lowering effect of repaglinide at a dosing level of 1.0 mg tid was better than that of nateglinide 90 mg tid on fasting blood glucose and A1c during 12 weeks treatment period, yet the insulinotropic effects of the two drugs were similar.
authors.affiliation: Division of Endocrinology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Li
authors.forename: Hao-ming
authors.initials: HM
authors.lastname: Tian
authors.forename: Hong-lin
authors.initials: HL
authors.lastname: Yu
authors.forename: Xiang-xun
authors.initials: XX
authors.lastname: Zhang
authors.forename: Gui-zhi
authors.initials: GZ
authors.lastname: Zhao
authors.forename: Jia-nan
authors.initials: JN
authors.lastname: Wang
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002219:Carbamates / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide